| [1] |
Gao Fan, Wang Ping, Du Chao, Chu Yanliu.
Research progress on intestinal flora and non-surgical treatment of the colorectal cancer
[J]. Journal of International Oncology, 2024, 51(6): 376-381.
|
| [2] |
Yue Hongyun, Zhang Baihong.
Differentiation therapies in human cancers
[J]. Journal of International Oncology, 2024, 51(2): 109-113.
|
| [3] |
Jin Xudong, Chen Zhongjian, Mao Weimin.
Research progress on the role of MTAP in malignant mesothelioma
[J]. Journal of International Oncology, 2024, 51(2): 99-104.
|
| [4] |
Li Chenxi, Zhao Hongwei.
Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery
[J]. Journal of International Oncology, 2023, 50(6): 342-347.
|
| [5] |
Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.
Research progress on the application of combining radiotherapy and systemic therapy in breast cancer
[J]. Journal of International Oncology, 2023, 50(6): 362-367.
|
| [6] |
Chen Yi, Han Liang, Cai Li.
Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors
[J]. Journal of International Oncology, 2022, 49(9): 521-525.
|
| [7] |
Yin Yunyan, Li Hui, Li Yuchen, Hui Hui, Xu Jingyan.
Clinical application of histone deacetylase inhibitors in non-Hodgkin lymphoma
[J]. Journal of International Oncology, 2022, 49(8): 499-504.
|
| [8] |
Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie.
Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer： a study based on real-world data
[J]. Journal of International Oncology, 2022, 49(7): 408-415.
|
| [9] |
Wang Liuxue, Xi Xiaoping, Liu Jingjing, Shen Guomin, Yang Haiping.
Research progress of metformin in non-Hodgkin lymphoma
[J]. Journal of International Oncology, 2022, 49(7): 436-440.
|
| [10] |
Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.
Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer
[J]. Journal of International Oncology, 2022, 49(5): 276-281.
|
| [11] |
Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu.
Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer
[J]. Journal of International Oncology, 2022, 49(3): 140-145.
|
| [12] |
Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng.
Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma
[J]. Journal of International Oncology, 2022, 49(11): 665-670.
|
| [13] |
Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin.
Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis
[J]. Journal of International Oncology, 2022, 49(1): 45-50.
|
| [14] |
Guo Yiwei, Liu Aichun.
Treatment of EB virus positive diffuse large B cell lymphoma
[J]. Journal of International Oncology, 2021, 48(7): 385-388.
|
| [15] |
Long Xin, Wu Han, Peng Jin, Zhou Fuxiang.
Systemic therapy of advanced biliary tract cancer
[J]. Journal of International Oncology, 2021, 48(5): 302-307.
|
